Experimental kidney drug MK-2060 passes first safety check in small study

NCT ID NCT05656040

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested a single shot of an experimental drug called MK-2060 in 14 people with stage 4 chronic kidney disease. The main goal was to see if it was safe and how the body handles it. Only the first part of the study was completed; the later parts were not started for reasons unrelated to safety. The drug is designed to affect blood clotting, so researchers closely watched for any bleeding problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-2060 (an experimental biologic given as a shot under the skin)
What this could lead to: If successful, MK-2060 could become a new option to help control blood clotting in people with advanced kidney disease.
What could go wrong: This is a very early Phase 1 study with only 14 participants, and only Part 1 was completed. The drug may not prove safe or effective in larger trials, and bleeding risks are a key concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE KIDNEY DISEASE END-STAGE RENAL DISEASE KIDNEY FAILURE, CHRONIC

Contacts and locations

Locations

Advanced Pharma CR, LLC ( Site 0006)

Miami, Florida, 33147, United States
Alliance for Multispecialty Research, LLC ( Site 0002)

Knoxville, Tennessee, 37920, United States
Genesis Clinical Research, LLC ( Site 0004)

Tampa, Florida, 33603, United States
Velocity Clinical Research, New Smyrna Beach ( Site 0003)

Edgewater, Florida, 32132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.